NASDAQ:VCEL Vericel (VCEL) Stock Forecast, Price & News $32.93 +0.27 (+0.83%) (As of 06/2/2023 08:49 PM ET) Add Compare Share Share Today's Range$32.49▼$33.3450-Day Range$28.16▼$35.1752-Week Range$17.30▼$35.73Volume252,700 shsAverage Volume342,275 shsMarket Capitalization$1.57 billionP/E RatioN/ADividend YieldN/APrice Target$37.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vericel MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside13.1% Upside$37.25 Price TargetShort InterestBearish11.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.29) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.00 out of 5 starsMedical Sector959th out of 980 stocksBiological Products, Except Diagnostic Industry162nd out of 163 stocks 2.3 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.25, Vericel has a forecasted upside of 13.1% from its current price of $32.93.Amount of Analyst CoverageVericel has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.96% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in Vericel has recently decreased by 2.18%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow in the coming year, from ($0.29) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -89.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -89.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 8.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vericel (NASDAQ:VCEL) StockVericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.Read More Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address VCEL Stock News HeadlinesMay 25, 2023 | americanbankingnews.comVericel (NASDAQ:VCEL) Reaches New 52-Week High at $35.53May 19, 2023 | americanbankingnews.comVericel (NASDAQ:VCEL) Now Covered by Analysts at StockNews.comJune 5, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 17, 2023 | americanbankingnews.comHC Wainwright Equities Analysts Boost Earnings Estimates for Vericel Co. (NASDAQ:VCEL)May 15, 2023 | markets.businessinsider.comBTIG Issues a Hold Rating on Vericel (VCEL)May 14, 2023 | americanbankingnews.comStephens Increases Vericel (NASDAQ:VCEL) Price Target to $42.00May 12, 2023 | americanbankingnews.comVericel (NASDAQ:VCEL) Price Target Raised to $36.00 at Truist FinancialMay 11, 2023 | msn.comStephens & Co. Maintains Vericel (VCEL) Overweight RecommendationJune 5, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 11, 2023 | msn.comTruist Securities Maintains Vericel (VCEL) Hold RecommendationMay 11, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Vericel (VCEL)May 10, 2023 | finanznachrichten.deVericel Corporation: Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceMay 10, 2023 | seekingalpha.comVericel Corporation 2023 Q1 - Results - Earnings Call PresentationMay 10, 2023 | finance.yahoo.comVericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceMay 9, 2023 | americanbankingnews.comVericel (VCEL) Scheduled to Post Earnings on WednesdayApril 26, 2023 | finance.yahoo.comVericel to Report First-Quarter 2023 Financial Results on May 10, 2023April 17, 2023 | finance.yahoo.comLittle Excitement Around Vericel Corporation's (NASDAQ:VCEL) RevenuesApril 2, 2023 | seekingalpha.comVericel Corporation: A Promising Future In Advanced Cell TherapiesFebruary 28, 2023 | finance.yahoo.comVericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023February 23, 2023 | finance.yahoo.comVericel Corporation (VCEL) Q4 Earnings Surpass EstimatesFebruary 23, 2023 | finance.yahoo.comVericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial GuidanceFebruary 12, 2023 | finance.yahoo.comVericel Corporation (VCEL) Stock Historical Prices & Data - Yahoo FinanceFebruary 9, 2023 | finance.yahoo.comVericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023January 31, 2023 | finance.yahoo.comVericel (NASDAQ:VCEL) shareholders are still up 275% over 5 years despite pulling back 5.7% in the past weekJanuary 12, 2023 | finance.yahoo.comVericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?January 10, 2023 | finance.yahoo.comVericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic ProgramJanuary 4, 2023 | finance.yahoo.comVericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023See More Headlines VCEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCEL Company Calendar Last Earnings2/23/2023Today6/04/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees281Year Founded1989Price Target and Rating Average Stock Price Forecast$37.25 High Stock Price Forecast$42.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+13.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,710,000.00 Net Margins-10.11% Pretax Margin-9.68% Return on Equity-9.26% Return on Assets-6.64% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio5.64 Sales & Book Value Annual Sales$163.70 million Price / Sales9.57 Cash FlowN/A Price / Cash FlowN/A Book Value$4.08 per share Price / Book8.07Miscellaneous Outstanding Shares47,560,000Free Float45,092,000Market Cap$1.57 billion OptionableOptionable Beta1.77 Social Links Key ExecutivesDominick C. ColangeloPresident, Chief Executive Officer & DirectorMichael HalpinChief Operating OfficerJoseph A. MaraChief Financial Officer & TreasurerJonathan Mark HopperChief Medical OfficerSean C. FlynnSecretary, Senior Vice President & General CounselKey CompetitorsKymera TherapeuticsNASDAQ:KYMRBioCryst PharmaceuticalsNASDAQ:BCRXRecursion PharmaceuticalsNASDAQ:RXRXSpringWorks TherapeuticsNASDAQ:SWTXPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 78,158 shares on 6/1/2023Ownership: 2.406%ProShare Advisors LLCBought 6,843 shares on 5/26/2023Ownership: 0.014%Ameriprise Financial Inc.Bought 31,587 shares on 5/22/2023Ownership: 1.486%JPMorgan Chase & Co.Sold 2,262 shares on 5/18/2023Ownership: 1.380%Thrivent Financial for LutheransBought 5,148 shares on 5/17/2023Ownership: 0.633%View All Insider TransactionsView All Institutional Transactions VCEL Stock - Frequently Asked Questions Should I buy or sell Vericel stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares. View VCEL analyst ratings or view top-rated stocks. What is Vericel's stock price forecast for 2023? 4 analysts have issued 1-year price targets for Vericel's stock. Their VCEL share price forecasts range from $34.00 to $42.00. On average, they anticipate the company's stock price to reach $37.25 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price. View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts. How have VCEL shares performed in 2023? Vericel's stock was trading at $26.34 at the beginning of the year. Since then, VCEL stock has increased by 25.0% and is now trading at $32.93. View the best growth stocks for 2023 here. When is Vericel's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our VCEL earnings forecast. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) posted its earnings results on Thursday, February, 23rd. The biotechnology company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.10. The biotechnology company had revenue of $52.70 million for the quarter, compared to the consensus estimate of $52.95 million. Vericel had a negative trailing twelve-month return on equity of 9.26% and a negative net margin of 10.11%. The business's revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.09 EPS. What ETFs hold Vericel's stock? ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), RiverFront Dynamic US Flex-Cap ETF (RFFC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has Vericel issued on next quarter's earnings? Vericel issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $184.00 million-$192.00 million, compared to the consensus revenue estimate of $186.54 million. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA). What is Vericel's stock symbol? Vericel trades on the NASDAQ under the ticker symbol "VCEL." Who are Vericel's major shareholders? Vericel's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.66%), Brown Capital Management LLC (14.81%), RTW Investments LP (6.92%), State Street Corp (5.74%), Conestoga Capital Advisors LLC (5.01%) and Fisher Asset Management LLC (3.66%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vericel's stock price today? One share of VCEL stock can currently be purchased for approximately $32.93. How much money does Vericel make? Vericel (NASDAQ:VCEL) has a market capitalization of $1.57 billion and generates $163.70 million in revenue each year. The biotechnology company earns $-16,710,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. How many employees does Vericel have? The company employs 281 workers across the globe. How can I contact Vericel? Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554. This page (NASDAQ:VCEL) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.